Ingredient · Evidence grade C
EstroG-100 for menopause: evidence, studies and safety
Last updated · 4 studies summarized
C Short answer: EstroG-100 is a Korean three-herb blend studied for occasional hot flashes and other common menopause symptoms* in three small placebo-controlled trials. The EU food-safety authority (EFSA) judged it safe only up to 175 mg a day, below the 514 mg a day used in most products.
Key facts
| Evidence grade | C C |
|---|---|
| Use studied | menopausal symptoms incl. hot flashes |
| Trials | 3 placebo RCTs (Chang 2012 n=64; Farzaneh 2024 n=120/70 analyzed; Snigdha 2025 n=80 combo with GABA) |
| Participants | ~264 randomized |
| What reviews conclude | No independent meta-analysis found. |
| The Menopause Society (2023) | Not specifically assessed (falls under 'supplements/herbal remedies – not recommended'). |
| Also known as | EstroG-100, Estro G-100 |
Grades: A strong · B moderate · C limited · D none or negative. How we grade.
Every study we reviewed
Each summary gives who took part, the dose, how long, the result compared with placebo or control, and who paid for it.
-
The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study.
64 US women took EstroG-100 (a Korean 3-herb blend) or placebo for 12 weeks. Overall symptom scores, including hot flashes and vaginal dryness, improved much more than with placebo. It is one small study and has not been widely repeated.
- Who
- 64 women (US, multi-ethnic)
- Dose
- EstroG-100 daily
- Duration
- 12 weeks
- Result
- Kupperman Index 29.5→11.3 vs 29.2→23.7 placebo (P<.01); vaginal dryness improved.
- Funding
- Not stated in abstract (ingredient maker Naturalendo Tech is the developer; not verified). Funding not stated
-
Estro G-100 herbal extract and hot flashes in postmenopausal women: A randomized double-blinded controlled trial.
In Iran, postmenopausal women took EstroG-100 or placebo; only 70 of 120 were analyzed. By week 6 the EstroG-100 group reported fewer hot flashes. The high drop-out rate weakens the result.
- Who
- 120 randomized, 70 analyzed (Iran)
- Dose
- EstroG-100 daily
- Duration
- 12 weeks (results reported at weeks 3–6)
- Result
- Fewer mild, moderate and severe hot flashes vs control at week 6 (P<.001).
- Funding
- Not stated in abstract. Funding not stated
-
Effect of a novel nutraceutical combination of EstroG-100 and γ-aminobutyric acid (GABA) in attenuating symptoms of menopause in healthy adult women: a randomized double-blinded placebo-controlled study.
80 women took OLLY's EstroG-100 + GABA product or placebo for 5 weeks. Hot flashes, sleep and mood improved more than placebo. The study was run by the company that sells the product.
- Who
- 80 women
- Dose
- EstroG-100 514 mg + GABA 50 mg (OLLY Mellow Menopause)
- Duration
- 5 weeks
- Result
- Hot-flash intensity and number fell vs placebo from days 1–2; sleep, mood and sexual function improved at later time points.
- Funding
- Authors are employees of OLLY PBC, the product's manufacturer. Industry-linked
-
Statement on the safety of EstroG-100™ as a novel food pursuant to Regulation (EC) No 258/97.
Europe's food-safety agency approved EstroG-100 only up to 175 mg a day – about a third of the dose used in many US products and trials – because of limited long-term safety data.
- Who
- n/a (EU safety opinion)
- Dose
- max 175 mg/day judged safe
- Duration
- n/a
- Result
- EFSA considered EstroG-100 safe at 175 mg/day in postmenopausal women (lower than the 514 mg/day proposed) because of liver/blood findings in animal studies and limited human data.
- Funding
- EFSA (independent EU regulator). Independent / academic
Safety
EFSA: safe only up to 175 mg/day in postmenopausal women (vs 514 mg/day used in many products) due to liver/haematology findings in animals and limited human data. Angelica species may interact with anticoagulants (dong quai concern noted by NAMS).
Ranked products that contain it
| Product | Amount per day | Score | $/day |
|---|---|---|---|
| Thorne Perimenopause Complete | EstroG-100 botanical blend: 514 mg | 64.6 | $1.73 |
| OLLY Mellow Menopause | EstroG-100 proprietary extract: 514 mg | 50.4 | $1.00 |
FAQ
Does EstroG-100 help with menopause symptoms?
EstroG-100 is a Korean three-herb blend studied for occasional hot flashes and other common menopause symptoms* in three small placebo-controlled trials. The EU food-safety authority (EFSA) judged it safe only up to 175 mg a day, below the 514 mg a day used in most products. Our evidence grade is C. No independent meta-analysis found.
Does The Menopause Society recommend EstroG-100?
Not specifically assessed (falls under 'supplements/herbal remedies – not recommended'). The 2023 nonhormone statement recommends no dietary supplement for hot flashes; talk to a clinician about hormone therapy and prescription options.
Is EstroG-100 safe?
EFSA: safe only up to 175 mg/day in postmenopausal women (vs 514 mg/day used in many products) due to liver/haematology findings in animals and limited human data. Angelica species may interact with anticoagulants (dong quai concern noted by NAMS). Supplements are not FDA-approved before sale; ask a clinician or pharmacist, especially if you take medication.
Sources
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.